NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

TENX

Tenax Therapeutics Inc

Jul 11 • 04:00PM ET

5.80

Dollar change +0.03
Percentage change 0.46	%

Healthcare • Biotechnology • USA • NASD

Peers: MRSN ACHV PBYI SCYX AVIR LXRX HURA EPIX PLX MRKR

| Held by: VXF DFSU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.48	Insider Own	12.50%	Shs Outstand	3.97M	Perf Week	-0.17%
Market Cap	24.06M	Forward P/E	-	EPS next Y	-2.83	Insider Trans	0.00%	Shs Float	3.63M	Perf Month	0.35%
Enterprise Value	-87.39M	PEG	-	EPS next Q	-0.27	Inst Own	56.09%	Short Float	9.28%	Perf Quarter	4.88%
Income	-24.21M	P/S	-	EPS this Y	-1.64%	Inst Trans	0.63%	Short Ratio	15.23	Perf Half Y	-9.52%
Sales	0.00M	P/B	0.21	EPS next Y	-142.08%	ROA	-38.27%	Short Interest	0.34M	Perf YTD	-6.30%
Book/sh	27.53	P/C	0.22	EPS next 5Y	-27.58%	ROE	-39.78%	52W High	7.89 -26.49%	Perf Year	81.82%
Cash/sh	26.87	P/FCF	-	EPS past 3/5Y	92.30% 77.86%	ROIC	-22.15%	52W Low	2.80 107.14%	Perf 3Y	-98.83%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.01% 7.62%	Perf 5Y	-99.61%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	89.91%	Oper. Margin	-	ATR (14)	0.36	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	40.48	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	40.48	EPS Q/Q	90.87%	SMA20	0.02%	Beta	1.45	Target Price	21.67
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-0.54%	Rel Volume	0.32	Prev Close	5.77
Employees	6	LT Debt/Eq	0.00	Earnings	May 14 AMC	SMA200	3.50%	Avg Volume	22.13K	Price	5.80
IPO	Apr 04, 1994	Option/Short	No / Yes	EPS/Sales Surpr.	-44.85% -	Trades		Volume	7,127	Change	0.46%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-24-24	Initiated	Leerink Partners	Outperform	$16
Oct-14-24	Initiated	Guggenheim	Buy	$16
Sep-30-24	Initiated	William Blair	Outperform
May-18-17	Upgrade	Ladenburg Thalmann	Neutral → Buy
Dec-16-14	Initiated	MLV & Co	Buy	$7
Nov-18-14	Initiated	WallachBeth	Buy	$12

May-14-25 04:38PM	Tenax Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-16-25 04:29PM	Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts (Seeking Alpha)
Mar-31-25 08:00AM	Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-25-25 04:25PM	Tenax Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-25 08:47AM	Tenax Therapeutics Announces $25 Million Private Placement (GlobeNewswire)
08:42AM	Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF (GlobeNewswire)
Mar-03-25 08:00AM	Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference (GlobeNewswire)
Jan-31-25 09:00AM	Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-22-25 08:00AM	Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations (GlobeNewswire)
Nov-13-24 07:19AM	Tenax Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-04-24 07:30AM	Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors (PR Newswire)
Oct-31-24 04:05PM	Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference (GlobeNewswire)
04:37PM	Loading…
Aug-13-24 04:37PM	Tenax Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +11.63%
04:05PM	Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-12-24 08:00AM	Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program (GlobeNewswire) -10.86%
Aug-06-24 07:13AM	Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement (GlobeNewswire) +28.77%
May-14-24 01:53PM	TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:10AM	Tenax Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-30-24 07:30AM	Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +6.27%
Apr-09-24 08:30AM	Tenax Therapeutics to Host KOL Event: LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study (GlobeNewswire)
Mar-28-24 09:54PM	TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +9.56% -9.91%
08:30AM	Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results (GlobeNewswire)
Mar-12-24 08:30AM	Tenax Therapeutics to Present at the 36th Annual Roth Conference (GlobeNewswire)
Feb-29-24 09:00AM	Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024 (GlobeNewswire) +10.87%
Feb-20-24 08:30AM	Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan (GlobeNewswire)
Feb-08-24 08:53AM	Why Is Tenax Therapeutics (TENX) Stock Down 64% Today? (InvestorPlace) -64.45%
08:16AM	Loading…
08:16AM	Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering (GlobeNewswire)
Feb-07-24 08:01PM	Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +24.54%
Feb-06-24 08:30AM	Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +31.31%
Dec-29-23 08:30AM	Tenax Therapeutics Announces Reverse Stock Split (GlobeNewswire) -16.79%
Nov-17-23 08:30AM	Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board (GlobeNewswire) -9.21%
Nov-14-23 05:05AM	Tenax Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -18.55%
Nov-13-23 03:22PM	Why Is Tenax Therapeutics (TENX) Stock Up 300% Today? (InvestorPlace) +297.44%
08:30AM	Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023 (GlobeNewswire)
Aug-28-23 08:20AM	TENX: Second Quarter Results (Zacks) -5.96%
Aug-25-23 07:20AM	7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole (InvestorPlace)
Jul-19-23 08:30AM	Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +10.40%
Jun-23-23 06:24AM	TENX: Notice of Allowance Increases Confidence (Zacks Small Cap Research) +9.19%
May-31-23 08:54AM	Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +13.31%
May-22-23 06:44AM	TENX: Prioritizing Levosimendan (Zacks Small Cap Research) +5.71%
Apr-21-23 03:59PM	10 Stocks Targeted By Short Sellers Recently (Insider Monkey)
Apr-12-23 02:50PM	Tenax Therapeutics Prioritizes Development Of TNX-103 For Heart Failure (Benzinga)
08:45AM	Tenax Therapeutics Provides 2023 Business Update (GlobeNewswire)
Apr-05-23 05:49AM	TENX: Patents Guide the Way (Zacks Small Cap Research) -7.89%
Mar-22-23 08:45AM	Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) -5.36%
Feb-17-23 07:05AM	Analysts Are Optimistic We'll See A Profit From Tenax Therapeutics, Inc. (NASDAQ:TENX) (Simply Wall St.)
Feb-15-23 08:05AM	TENX: New Funding Puts Wind in the Sails (Zacks Small Cap Research)
Feb-07-23 12:10PM	Triangle pharma raising millions amid uncertain future (American City Business Journals) -8.02%
Feb-03-23 08:19AM	Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering (GlobeNewswire) -20.81%
Feb-02-23 10:43AM	Why Tenax Therapeutics Shares Are Gaining Today? (Benzinga) +30.77%
Feb-01-23 04:31PM	Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) -20.28%
Jan-04-23 08:00AM	Tenax Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Nov-03-22 07:16AM	TENX: Agility Required to Unlock Considerable Upside (Zacks Small Cap Research) -20.03%
Oct-10-22 08:30AM	Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire)
Sep-15-22 09:29AM	Tenax Therapeutics Stock Jumps On Strategic Alternative Review (Benzinga) +11.25%
08:30AM	Tenax Therapeutics Announces the Evaluation of Strategic Alternatives (GlobeNewswire)
Aug-28-22 09:23AM	Loss-Making Tenax Therapeutics, Inc. (NASDAQ:TENX) Expected To Breakeven In The Medium-Term (Simply Wall St.)
Aug-23-22 05:58AM	TENX: The Pressures On: Awaiting Phase 3 Start (Zacks Small Cap Research)
Jul-01-22 07:52AM	Chapel Hill company given extension to regain Nasdaq compliance (American City Business Journals) +6.07%
May-25-22 08:30AM	Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH) (Business Wire)
May-23-22 08:30AM	Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension (Business Wire) +6.92%
May-19-22 08:18AM	TENX: 1Q:22 Financial and Operational Review (Zacks Small Cap Research)
May-18-22 08:30AM	Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules (Business Wire) +7.27%
Apr-01-22 09:25AM	TENX: 2021 Financial and Operational Review (Zacks Small Cap Research)
Mar-31-22 08:30AM	Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update (Business Wire)
Mar-30-22 05:00PM	Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions (Business Wire)
Jan-31-22 04:10PM	Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors (GlobeNewswire)
Jan-12-22 08:30AM	Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102) (GlobeNewswire)
Jan-05-22 11:48AM	TENX: TNX-103 & TNX-201 Near Ready for Phase III (Zacks Small Cap Research)
Jan-04-22 08:30AM	Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs (GlobeNewswire) -9.01%
Nov-18-21 11:54AM	TENX: Imatinib IND Cleared & PK Study Near End (Zacks Small Cap Research) -5.22%
Nov-16-21 08:30AM	Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update (Business Wire)
Oct-06-21 08:30AM	Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH) (Business Wire)
Sep-28-21 08:30AM	Tenax Therapeutics to Present at the Benzinga Healthcare Small Cap Conference (Business Wire) +7.69%
Sep-20-21 10:43AM	TENX: Second Quarter Results (Zacks Small Cap Research) -6.57%
Sep-09-21 08:00AM	Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (Business Wire)
Aug-17-21 08:00AM	Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update (Business Wire)
Aug-12-21 08:00AM	Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF) (Business Wire) -5.49%
Aug-05-21 08:00AM	Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (Business Wire) +5.73%
Jul-16-21 12:40PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tenax Therapeutics, Inc - TENX (Newsfile)
Jul-07-21 08:00AM	Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules (Business Wire)
Jun-14-21 04:25PM	Hedge Funds Are Selling Tenax Therapeutics Inc (TENX) (Insider Monkey)
Jun-10-21 08:30AM	Tenax Therapeutics Set to Join Russell Microcap® Index (Business Wire)
Jun-07-21 04:52PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tenax Therapeutics, Inc - TENX (Newsfile)
May-17-21 05:15PM	Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update (Business Wire) -6.73%
Apr-14-21 07:45AM	TENX: HELP Results & New Asset to Boot (Zacks Small Cap Research)
Apr-09-21 11:38AM	Tenax Rises on Progress With Hypertension Treatment (TheStreet.com) +16.85%
08:00AM	Tenax Announces Publication Titled "Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial " (Business Wire)
Apr-07-21 04:45PM	Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders (Business Wire)
Mar-31-21 04:45PM	Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update (Business Wire)
Mar-04-21 08:30AM	Tenax Therapeutics to Present at the H.C. Wainwright Global Life Sciences Virtual Conference (Business Wire) -10.60%
Mar-02-21 08:15AM	Tenax Therapeutics, Inc. Expands Board of Directors (Business Wire)
Jan-20-21 10:30AM	TENX: Tenax Picks Up PH Precision Med (Zacks Small Cap Research)
07:45AM	Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med (Business Wire)
Jan-19-21 07:45AM	Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med (Business Wire) +32.58%
Dec-29-20 04:29PM	5 Top Stock Gainers for Tuesday: Snap, Barnes & Noble Education (TheStreet.com) +85.05%

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TENX

Tenax Therapeutics Inc

Upgrade your FINVIZ experience